Mark A Goldsmith sold $3.9M of RVMD
See Remarks at Revolution Medicines, Inc.. 70,000 shares at an average of $55.41, traded Nov 1, 2024, filed Nov 5, 2024.
Score components
- +15RoleOfficer
- +25Trade size$3.9M at market
- +5Share of holdings soldSold 23% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -16.7%, 3m -25.4%, 6m -34.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001610717-24-000517, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 1, 2024 | MOption exercise Common Stock10b5-1 | +9,100 | $4.09 | $37k | 309,270 | Nov 5, 2024 |
| Nov 1, 2024 | SOpen-market sale Common Stock10b5-1 | -9,100 | $55.02 | $501k | 300,170 | Nov 5, 2024 |
| Nov 1, 2024 | SOpen-market sale Common Stockindirect: Trust10b5-1 | -5,000 | $55.03 | $275k | 20,424 | Nov 5, 2024 |
| Nov 1, 2024 | SOpen-market sale Common Stockindirect: Trust10b5-1 | -5,000 | $55.02 | $275k | 20,424 | Nov 5, 2024 |
| Nov 4, 2024 | MOption exercise Common Stock10b5-1 | +50,900 | $4.09 | $208k | 351,070 | Nov 5, 2024 |
| Nov 4, 2024 | SOpen-market sale Common Stock10b5-1 | -50,900 | $55.56 | $2.8M | 300,170 | Nov 5, 2024 |
| Nov 4, 2024 | MOption exercise Common Stock10b5-1 | +36,600 | $0.49 | $18k | 336,770 | Nov 5, 2024 |
| Nov 1, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -9,100 | $0.00 | $0 | 232,129 | Nov 5, 2024 |
| Nov 4, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -50,900 | $0.00 | $0 | 181,229 | Nov 5, 2024 |
| Nov 4, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -36,600 | $0.00 | $0 | 30,846 | Nov 5, 2024 |
Related signals
Other insiders at Revolution Medicines, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | Revolution Medicines, Inc. | Alan B. Sandler Chief Development Officer | $1.3M 6,309 shares | -11% | |
| 21Weak | Revolution Medicines, Inc. | Jeff Cislini SVP & General Counsel | $159k 765 shares | -1% | |
| 16Weak | Revolution Medicines, Inc. | Anthony Mancini See Remarks | $743k 3,708 shares | -9% | |
| 40Moderate | Revolution Medicines, Inc. | Elizabeth M Anderson director | $2.0M 10,143 shares | -70% | |
| 25Weak | Revolution Medicines, Inc. | Anthony Mancini See Remarks | $347k 1,764 shares | -4% | |
| 39Weak | Revolution Medicines, Inc. | Jack Anders Chief Financial Officer | $808k 4,053 shares | -3% | |
| 30Weak | Revolution Medicines, Inc. | Jeff Cislini SVP & General Counsel | $671k 3,366 shares | -6% | |
| 35Weak | Revolution Medicines, Inc. | Mark A Goldsmith See Remarks | $2.8M 13,988 shares | -5% | |
| 40Moderate | Revolution Medicines, Inc. | Margaret A Horn Chief Operating Officer | $990k 4,967 shares | -3% | |
| 35Weak | Revolution Medicines, Inc. | Stephen Michael Kelsey See Remarks | $1.1M 5,569 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.